Flash Finance

Viyash Scientific LimitedVIYASHCorporate

Drug Manufacturers - Specialty & Generic Latest results: Mar 2026 14 quarters of data
Consolidated Standalone
₹226.00
MCap ₹9,946 Cr · P/E 234.8
Viyash Scientific Limited — Stock analysis & AI research Viyash Scientific Limited — Multibagger AI analysis Viyash Scientific Limited — Seasonality — best & worst months Viyash Scientific Limited — Technical indicators & charts Viyash Scientific Limited — Technical setup — score, trend, support & resistance Viyash Scientific Limited — Live exchange announcements
📋 High Sales Growth Stocks📋 High Profit Growth Stocks 📈 MACD Bearish Crossover📈 Lowest Technical Score 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹372 Cr
Sales · Mar 2026
+778.8% YoY
₹63 Cr
Operating Profit · Mar 2026
16.9%
OPM % · Mar 2026
₹36 Cr
Net Profit · Mar 2026
+751.1% YoY
₹0.82
EPS · Mar 2026

📝 Viyash Scientific Limited — results explained

Quarter ended March 2026 (Q4 FY26)

Viyash Scientific Limited reported revenue of ₹372 crore for the quarter ended March 2026 (Q4 FY26), up 778.8% from ₹42 crore in the same quarter last year, and up 8.9% sequentially over the December 2025 quarter.

Net profit rose 751.1% year-on-year to ₹36 crore, from ₹4 crore. Earnings per share (EPS) came in at ₹0.82.

Operating profit stood at ₹63 crore — an operating margin (OPM) of 16.9%.

Full year and trailing twelve months

For the full year FY26, Viyash Scientific Limited posted revenue of ₹789 crore, a growth of 342.4% over FY25, with a net profit of ₹42 crore (up 172.7% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹789 crore with a net profit of ₹42 crore.

Valuation snapshot

At the current price of ₹226.00, VIYASH has a market capitalisation of ₹9,946 crore and a trailing P/E of about 234.8.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 25th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 49.24%, foreign institutional investors (FIIs) 2.60%, domestic institutional investors (DIIs) 8.30%, public shareholders 39.76% of Viyash Scientific Limited.

Promoter holding slipped from 61.31% to 49.24% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹9,946 Cr
Current Price ?
₹226.0
P/E ?
234.75above ind
Industry P/E ?
35.00
P/B ?
3.12
P/S ?
12.61
P/FCF ?
198.93
Enterprise Value ?
₹9,979 Cr
EV/EBITDA ?
N/A
PEG ?
1.40
Earnings Yield ?
0.4%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹789 Cr
OPM ?
N/A
Profit after tax (TTM) ?
₹42 Cr
EPS (TTM) ?
₹0.96
ROCE ?
8.0%
ROE ?
1.3%
ROA ?
1.2%
Growth
Sales — latest qtr ?
₹372 Cr
PAT — latest qtr ?
₹36 Cr
YoY qtr sales growth ?
778.8%
YoY qtr profit growth ?
751.1%
Sales growth (3y) ?
84%
Sales growth (5y) ?
39%
Profit growth (3y) ?
168%
Profit growth (5y) ?
26%
Financial Health
Debt ?
₹33 Cr
Debt to Equity ?
0.01
Interest Coverage ?
10.8
Current Ratio ?
N/A
Ownership
Promoter holding ?
49.24%
Change in promoter holding ?
-3.37%
Pledged percentage ?
N/A
Market
Return 3 months ?
-15.9%
Return 6 months ?
8.5%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026 YoY % QoQ %
Sales 574740494237584236424134342372 +778.8% +8.9%
Operating Profit ——-9-8-4——-2————7063 — -10.4%
Other Income ——31013——12————1620 — +22.8%
Interest ——111——1————43 — -15.7%
Depreciation ——222——2————3131 — -0.6%
Profit Before Tax -4-1-9-1646646541149 +729.1% +361.8%
Net Profit -1-2-7-154443433-036 +751.1% +45100.0%
EPS ——-0.27-0.040.18——0.17————0.000.82 — —
OPM % — — -22.5% -15.7% -9.5% — — -4.8% — — — — 20.6% 16.9% — -18.0%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹178 Cr ₹789 Cr ₹789 Cr +342.4%
Operating Profit ₹-2 Cr ₹133 Cr ₹133 Cr +6767.0%
OPM % -1.12% 16.91% 16.91% +1609.8%
NPM % 8.72% 5.37% 5.37% -38.4%
Other Income ₹12 Cr ₹36 Cr ₹36 Cr +202.4%
Depreciation ₹2 Cr ₹62 Cr ₹62 Cr +3010.0%
Interest ₹1 Cr ₹7 Cr ₹7 Cr +556.0%
EBIT ₹-4 Cr ₹71 Cr ₹71 Cr +1878.5%
PBT ₹22 Cr ₹69 Cr ₹69 Cr +217.6%
Tax — ₹11 Cr ₹11 Cr —
Net Profit ₹16 Cr ₹42 Cr ₹42 Cr +172.7%
EPS ₹0.17 ₹0.82 ₹0.82 +382.4%
Material Cost — ₹160 Cr ₹160 Cr —
Employee Cost — ₹50 Cr ₹50 Cr —
Extraordinary Items — ₹-44 Cr ₹-44 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 50505087 +74.0%
Reserves 1,0081,0371,0933,102 +183.8%
Borrowings 20474633 -28.3%
Other Liabilities 445434433 +1173.5%
Total Liabilities 1,1231,1881,2223,655 +199.1%
Fixed Assets 5743461,162 +2426.1%
CWIP 25755 +685.7%
Investments 633640647977 +51.0%
Other Assets 4315005221,460 +179.7%
Total Assets 1,1231,1881,2223,655 +199.1%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 38-27-1119 +12000.0%
Cash from Investing Activity -515-0-107 —
Cash from Financing Activity 0221-7 -800.0%
Net Cash Flow -131-15 +600.0%
Free Cash Flow 29-12-1050 +600.0%
CFO/OP -146%110%39%56% +43.6%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 2297141146 +3.5%
Inventory Days 12911787171 +96.6%
Days Payable 9912679182 +130.4%
Cash Conversion Cycle 5388148136 -8.1%
Working Capital Days 22-564135 +110.9%
ROCE % -1%1%2%8% +300.0%

👥 Shareholding (latest 6 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026 % Chg
Promoters 52.61%52.33%61.41%61.31%61.31%49.24% -19.7%
FIIs 6.15%5.90%3.16%2.94%4.50%2.60% -42.2%
DIIs 12.98%12.91%7.36%7.98%3.75%8.30% +121.3%
Public 28.10%28.69%27.97%27.67%30.34%39.76% +31.0%
No. of Shareholders 1,47,3201,44,0851,34,1941,27,4461,28,3671,42,732 +11.2%
Others 0.16%0.16%0.09%0.09%—— —

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 VIYASH Viyash Scientific ₹258.85 11,392 105.1 2,253 136 18.3% 6.0% 88.2% 387.6% 128.9% 560.0%
❓ Frequently asked questions
What was Viyash Scientific Limited's revenue in Q4 FY26?
Viyash Scientific Limited reported revenue of ₹372 crore for the quarter ended March 2026 (Q4 FY26), up 778.8% from ₹42 crore in the same quarter last year, and up 8.9% sequentially over the December 2025 quarter.
What was Viyash Scientific Limited's net profit in Q4 FY26?
Net profit rose 751.1% year-on-year to ₹36 crore, from ₹4 crore. Earnings per share (EPS) came in at ₹0.82.
What is VIYASH's market capitalisation and P/E ratio?
At the current price of ₹226.00, VIYASH has a market capitalisation of ₹9,946 crore and a trailing P/E of about 234.8.
Who owns Viyash Scientific Limited? (shareholding pattern)
As of Sep 2026, promoters held 49.24%, foreign institutional investors (FIIs) 2.60%, domestic institutional investors (DIIs) 8.30%, public shareholders 39.76% of Viyash Scientific Limited.
TTM ends 2026-03-31. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI